
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is a clinical-stage biotechnology company with a pioneering program in detalimogene voraplasmid for Non-Muscle Invasive Bladder Cancer, a disease with high clinical burden. The company's Dually Derivatized Oligochitosan platform offers potential differentiation through low treatment interruption rates and simple handling, potentially appealing to community urology practices. While the latest efficacy data declined significantly, safety remains highly favorable and the company is on track for potential approval decision in 2027 pending durability updates in late 2026.
Bears say
enGene Therapeutics is facing numerous challenges and uncertainties with their gene therapy drug for bladder cancer, including weaker-than-expected durability, a lack of confidence in the mechanism of action, and increased regulatory and commercial risks. These factors have led to a revision of their price target to $4, down from $6, and a downgrade to a Neutral rating. Additionally, the company's financial risk and potential competition from larger companies could also impact their future success. Despite some potential advantages in the market, the company faces significant obstacles in achieving a meaningful market share in the highly competitive NMIBC market.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares